Sound Pharmaceuticals is a bio-pharmaceutical platform developing novel treatments to prevent and treat hearing loss and tinnitus. The company uses molecular biology, immunohistochemistry and electrophysiology that have lead to the development of preclinical models of hearing loss and tinnitus that are translating into successful clinical trials.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/24/2018 | Series C-2 | $11.76MM | $xx.xx | $47.84MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,920,237
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
10/17/2013 | Series C-1 | $2MM | $xx.xx | $44.29MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
10/17/2013 | Series C | $9.18MM | $xx.xx | $44.29MM | KEC Ventures | |
Price per Share
$xx.xx
Shares Outstanding
3,058,345
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
KEC Ventures
|
||||||
07/06/2006 | Series B | $3MM | $xx.xx | $9.5MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,000,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
06/30/2001 | Series A | $16,000 | $xx.xx | $396,928 | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
800,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|